Integrative Approaches to Cancer Immunotherapy

Szeto, Gregory L.; Finley, Stacey D.

doi:10.1016/j.trecan.2019.05.010

Cited by 107 publications

(72 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer immunotherapy, defined as the fourth pillar of human cancer therapy, next to surgery, chemotherapy, and radiotherapy, aims to coopt the immune system to combat cancer and puts down its roots back in 1890 when Coley proved that injection of bacteria or bacterial lysates promoted remission in patients with malignant sarcomas (Szeto & Finley, 2019). Despite these early results, the development of cancer immunotherapy was delayed by the prevailing use of strategies aimed at combating the tumor cells directly rather than promoting an inflammatory response (Ritter & Greten, 2019).…”

Section: Introductionmentioning

confidence: 99%

Thymosin α1 protects from CTLA-4 intestinal immunopathology

et al. 2020

View full text Add to dashboard Cite

The advent of immune checkpoint inhibitors has represented a major boost in cancer therapy, but safety concerns are increasingly being recognized. Indeed, although beneficial at the tumor site, unlocking a safeguard mechanism of the immune response may trigger autoimmune-like effects at the periphery, thus making the safety of immune checkpoint inhibitors a research priority. Herein, we demonstrate that thymosin α1 (Tα1), an endogenous peptide with immunomodulatory activities, can protect mice from intestinal toxicity in a murine model of immune checkpoint inhibitor–induced colitis. Specifically, Tα1 efficiently prevented immune adverse pathology in the gut by promoting the indoleamine 2,3-dioxygenase (IDO) 1–dependent tolerogenic immune pathway. Notably, Tα1 did not induce IDO1 in the tumor microenvironment, but rather modulated the infiltration of T-cell subsets by inverting the ratio between CD8+ and Treg cells, an effect that may depend on Tα1 ability to regulate the differentiation and chemokine expression profile of DCs. Thus, through distinct mechanisms that are contingent upon the context, Tα1 represents a plausible candidate to improve the safety/efficacy profile of immune checkpoint inhibitors.

show abstract

Section: Introductionmentioning

confidence: 99%

Thymosin α1 protects from CTLA-4 intestinal immunopathology

et al. 2020

View full text Add to dashboard Cite

show abstract

“…472 It aims to use T-cell-activating cytokines, immune checkpoint inhibitors, regulatory T cell depletion, and chimeric antigen receptor to selectively inhibit tumor growth. 473,474 Cancer immunotherapy cannot directly kill tumor cells, but it can indirectly kill tumor cells by stimulating immune cell activation, proliferation, and differentiation. A large number of clinical trials and clinical practices have conrmed the effectiveness of this method for specic populations, although the side-effects are not less than those of traditional chemotherapy to a certain extent.…”

Section: Combination Therapymentioning

confidence: 99%

Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Immunotherapy has revolutionized both the cancer research and treatment landscape by targeting the host immune system (Coutzac et al, 2019;Szeto and Finley, 2019). Antibodies targeting to blocking immune checkpoints such as programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) have proven efficacies in diverse solid cancers.…”

Section: Machine Learning In Gastric Cancer Researchmentioning

confidence: 99%

Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment

Shi

Wei

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

Gastric cancer is the fifth most diagnosed cancer in the world, affecting more than a million people and causing nearly 783,000 deaths each year. The prognosis of advanced gastric cancer remains extremely poor despite the use of surgery and adjuvant therapy. Therefore, understanding the mechanism of gastric cancer development, and the discovery of novel diagnostic biomarkers and therapeutics are major goals in gastric cancer research. Here, we review recent progress in application of omics technologies in gastric cancer research, with special focus on the utilization of systems biology approaches to integrate multi-omics data. In addition, the association between gastrointestinal microbiota and gastric cancer are discussed, which may offer insights in exploring the novel microbiota-targeted therapeutics. Finally, the application of datadriven systems biology and machine learning approaches could provide a predictive understanding of gastric cancer, and pave the way to the development of novel biomarkers and rational design of cancer therapeutics.

show abstract

Integrative Approaches to Cancer Immunotherapy

Cited by 107 publications

References 64 publications

Thymosin α1 protects from CTLA-4 intestinal immunopathology

Thymosin α1 protects from CTLA-4 intestinal immunopathology

Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications

Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment

Contact Info

Product

Resources

About